Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat

NeuroReport

Volumn 11, Issue 1, 2000, Pages 49-55

  Garry, Mary G ^a   Malik, Sundeep ^b   Yu, Jie ^b   Davis, Michael A ^c   Yang, Jay ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NONE

Author keywords

Antinociceptive; Antisense; Formalin; Intrathecal; NMDA RI

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FORMALDEHYDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBUNIT;

ADVANCED CANCER; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CELL STRAIN; CHRONIC PAIN; CONTROLLED STUDY; GENE THERAPY; INFLAMMATORY DISEASE; MALE; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034677145     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200001170-00010     Document Type: Article

References (47)

1. Grond S, Zech D, Diefenbach C and Bischoff A. J Pain Symptom Management 9, 372-382 (1994).
2. Hiraga K, Mizuguchi T and Takeda F. Postgrad Med J 67, S14-S25 (1991).
3. Somerville MA. Death of pain: Pain, suffering, and ethics. In: Gebhart GF, Hammond DL and Jensen TS, eds. Proceedings of the 7th World Congress on Pain. Seattle: IASP Press, 1994.
4. Cherny NI and Portenoy RK. Cancer 72, 3393-415 (1993).
5. Dray A, Urban L and Dickenson A. Trends Pharmacol Sci 15, 190-197 (1994).
6. Zenz M and Willweber-Strumpf A. Lancet 341, 1075-1076 (1993).
7. Ganong AH, Lanthorn TH and Cotman CW. Brain Res 273, 170-174 (1983).
8. Jahr CE and Jessel TM. J Neurosci 5, 2881-2289 (1985).
9. Morris R. Neurosci Lett 105, 79-85 (1989).
10. Long SK, Smith DAS, Siarey RJ and Evans RH. Br J Pharmacol 100, 850-854 (1990).
11. Dickenson AH and Sullivan AF. Neuropharmacology 26, 1235-1238 (1987).
12. Watkins JC and Evans RH. Annu Rev Pharmacol Toxicol 21, 165-204 (1981).
13. Watkins JC. Trends Pharm Sci 5, 373-376 (1984).
14. Aanonsen LM and Wilcox GL. J Pharm Exp Ther 243, 9-19 (1987).
15. Meller ST, Dykstra C and Gebhart GF. Eur J Pharmacol 214, 93-96 (1992).
16. Kitto KF, Haley JE and Wilcox GL. Neurosci Lett 148, 1-5 (1992).
17. Skilling SR, Smullin DH, Beitz AJ and Larson AA. J Neurochem 51, 127-132 (1988).
18. Sorkin LS, Westlund KN, Sluka KA et al. Brain Res Rev 17, 39-50 (1992).
19. Sluka KA, Jordan HH, Willis WD and Westlund KN. Brain Res 664, 77-84 (1994).
20. Schaible H-G, Grubb BD, Neugebauer V and Oppmann M. Eur J Neurosci 3, 981-991 (1991).
21. Ren K, Hylden JKL, Williams GM et al. Eur J Pharmacol 219, 235-243 (1992).
22. Murray CW, Cowan A and Larson AA. Pain 44, 179-185 (1991).
23. Woolf CJ and Thompson SWN. Pain 44, 293-300 (1991).
24. Yamamoto T and Yaksh TL. Pain 49, 121-128 (1992).
25. Kutsuwada T, Kashiwabuchi N, Mori H et al. Nature 358, 36-41 (1992).
26. Moyner H, Sprengel R, Schoepfer R et al. Science 256, 1217-1221 (1992).
27. Moriyoshi K, Masu M, Ishii T et al. Nature 354, 31-37 (1991).
28. Sakurada K, Masu M and Nakanishi S. J Biol Chem 268, 410-415 (1993).
29. Buchan AM. Cerebrovasc Brain Metab Rev 2, 1-26 (1990).
30. Olney JW, Labruyere J, Wang G et al. Science 244, 1360-1362 (1989).
31. Olney JW, Labruyere J, Wang G et al. Science 254, 1515-1518 (1991).
32. Wahlestedt C, Golanov E, Yamamoto S et al. Nature 363, 260-263 (1993).
33. Wahlestedt C. Trends Pharm Sci 15, 42-45 (1994).
34. Soltesz I, Zhou Z and Mody I. Neurosci Lett 181, 5-8 (1994).
35. Zapata A, Capdevila JL, Taffason G et al. Brain Res 745,114-120 (1997).
36. Sun, Feng-Yan, Faden AI. Brain Res 693, 163-168 (1995).
37. Matthies H, Schroder H, Wagner M et al. Neurosci Lett 202, 113-116 (1995).
38. Yaksh TL and Rudy TA. Physiol Behav 17, 1031-1036 (1976).
39. Liu H, Mantyh PW and Basbaum AI. Nature 386, 721-724 (1997).
40. Williams SA, Gillan ER, Knoppel E et al. Ann Oncol 8 (Suppl. 1), 25-30 (1997).
41. Schmidt A, Sindermann J, Peyman A et al. Eur J Biochem 248, 543-549 (1997).
42. Casado M and Ascher P. J Physiol 513, 317-330 (1998).
43. Kolhekar R, Murphy S and Gebhart GF. Pain 71, 31-40 (1997).
44. Fraser GL and Wahlestedt C. Prog Pain Res Manag 9, 319-336 (1997).
45. Hua X, Chen P, Polgar E et al. J Neurochem 70, 688-698 (1998).
46. Broaddus WC, Prabhu SS, Gillies GT et al. J Neurosurg 88, 734-742 (1998).
47. Crooke ST. Advances in understanding the pharmacological properties of antisense oligonucleotides. In: Weiss B, ed. Antisense Oligodeoxynucleotides and Antisense RNA. New York: CRC Press, 1997: 17-55.